News & Press | February 9, 2026

NULISAqpcr™ AD 5-plex Assay for Alzheimer’s Biomarkers

Get the Resource

NULISAqpcr AD 5-plex Assay Request

Submit your request for a quote or more information on the AD 5-plex Assay.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Now offered by Sapient – an Alamar Certified Service Provider

The NULISAqpcr AD 5-plex Assay provides absolute quantitation of established amyloid-β-tau-neurodegeneration (ATN) & neuroinflammatory (I) biomarkers in a single multiplexed assay.

This innovative panel enables simultaneous measurement of key Alzheimer’s disease (AD)–related biomarkers – including brain-derived phosphorylated tau 217 (BD-pTau217), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) to comprehensively monitor amyloid and tau pathology, neurodegeneration, and inflammation. It also includes measurement of APOE4 to determine carrier status of this genetic variant, which is the strongest genetic risk factor for AD and amyloid related imaging abnormalities (ARIA).

Biomarkers in the NULISAqpcr AD 5-plex Assay

In a single blood sample and with one streamlined workflow, we can reliably detect low‑abundance biomarkers across pathways and processes that are most relevant in Alzheimer’s disease biology.

Biomarker Biological Relevance Applications
APOE4 The strongest known inherited genetic risk factor for late-onset AD and ARIA
  • Determine APOE carrier status
  • Stratify patients & personalize interventions
BD-pTau217 Elevated levels reflect the presence of tau tangles, which are a defining feature of Alzheimer’s disease pathology
  • Early disease detection
  • Longitudinal monitoring of disease dynamics
Aβ42 Reduced levels in blood associate with increased Aβ plaque in the brain, an early indicator of disease development
  • Track disease progression
  • Monitor response to amyloid-targeting therapies
GFAP Elevated levels indicate astroglial activation which can amplify neuroinflammatory
  • Track disease progression
  • Monitor response to amyloid-targeting therapies
NfL Released into the blood when neurons are damaged or are undergoing degeneration
  • Neuronal damage / disease monitoring
  • Drug response monitoring

Together, these biomarkers provide a multidimensional view of amyloid and tau pathology, neuroinflammation, and neurodegeneration – allowing for integrated assessment of AD and dementia via a single assay.

Setting a new standard for precision

The NULISAqpcr™ platform combines single‑molecule sensitivity with exceptional specificity, enabling reliable detection of low‑abundance biomarkers like BD-pTau217 (originating from the CNS) with attomolar (fg/mL) sensitivity in plasma.

In fact, the assay shows high correlation with the NULISAseq CNS Disease Panel 120 in its ability to provide high sensitivity and specificity for disease group stratification, as well as high correlation with APOE4 genotyping.

nulisa AD 5-plex assay data

Why choose Sapient for the AD 5-plex Assay?

As an Alamar Certified Service Provider, Sapient has demonstrated proficiency in executing the NULISAqpcr™ platform, delivering absolute quantitation of key CNS disease biomarkers with proven technical rigor and assay fidelity. All analysis for this assay is done in-instrument at our lab site, allowing for rapid turnaround of results.

In addition, we can offer a broader range of actionable omics data through our complementary proteomics and metabolomics services. These approaches allow for orthogonal validation of NULISA data and can also deliver deeper mechanistic context to your study findings with added layers of protein- and metabolite-level insights.

Whether your goal is early detection, pathway interrogation, or functional evidence for translation, we can help you leverage the NULISAqpcr AD 5‑plex Assay as a single solution or as part of a broader multi-omics study for:

  • Biomarker discovery and validation
  • Preclinical and translational research
  • Patient stratification and risk assessment
  • Proof of mechanism
  • Longitudinal disease progression monitoring

Accelerate your AD research – get started today

Accelerate your Alzheimer’s research with the power of the NULISAqpcr AD 5-plex Assay, and with the confidence of Sapient as your expert partner to deliver robust, quality biomarker data for stronger decision‑making in your studies.

Use the form to request the assay or provide more information on your study requirements. You can also email discover@sapient.bio to set up a time to talk about your needs.

Get the Resource

NULISAqpcr AD 5-plex Assay Request

Submit your request for a quote or more information on the AD 5-plex Assay.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Follow Us